POSA133 Cost-Effectiveness of Dapagliflozin for the Treatment of Heart Failure with Reduced Ejection Fraction: Analyses from the Perspectives of France and the United States
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.276
https://www.valueinhealthjournal.com/article/S1098-3015(21)02071-4/fulltext
Title :
POSA133 Cost-Effectiveness of Dapagliflozin for the Treatment of Heart Failure with Reduced Ejection Fraction: Analyses from the Perspectives of France and the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02071-4&doi=10.1016/j.jval.2021.11.276
First page :
Section Title :
Open access? :
No
Section Order :
11056